Drug intelligence / Profile preview

SBC118

Development stage: Unknown
Lead developer: SapiensBio

Overview

SBC118 is an investigational therapeutic candidate being developed by SapiensBio for the treatment of liver fibrosis. Identified through SapiensBio's proprietary drug discovery platform, the asset is currently in Phase 2 clinical development. While specific details regarding its molecular target and modality have not been widely disclosed in public pipeline summaries, it is positioned as a lead program for addressing fibrotic liver diseases. SapiensBio typically utilizes an AI-driven approach to identify novel small molecule candidates, though the exact modality for SBC118 remains proprietary.

Beyond the preview

Go deeper on SBC118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC118.

Explore the full profile